Advice
Following a full submission
raltegravir (Isentress) is accepted for restricted use within NHS Scotland in combination with other antiretroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV-1) infection in treatment experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. It is restricted to patients with triple class resistant HIV-1 infection.
Addition of raltegravir to optimised background therapy in treatment experienced patients with documented resistance to at least one drug in each of the three HIV antiviral classes, significantly increased the number of patients achieving clinically significant reductions in viral load.
Download detailed advice75KB (PDF)
Medicine details
- Medicine name:
- raltegravir (Isentress)
- SMC ID:
- 461/08
- Indication:
- in combination with other antiretroviral medicinal products agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in treatment experienced adult patients
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 May 2008